

January 7, 2013



## Oragenics CEO To Present at 6th Annual OneMedForum Investor Conference

TAMPA, Fla.-- [Oragenics, Inc.](#) (OTCQB:OGEN) (OTCBB:OGEN), today announced Dr. John Bonfiglio, President and CEO of Oragenics, Inc., will present an overview of the company at the 6<sup>th</sup> Annual [OneMedForum](#) in San Francisco on Tuesday, January 8<sup>th</sup> at 12:00 pm PST. Launched in 2008 by OneMedPlace, OneMedForum runs concurrently with the 31st Annual J.P. Morgan Healthcare Conference and brings together leading investors, strategic partners and management of some of the most promising emerging life science companies in Asia and North America.

John N. Bonfiglio, PhD President and CEO Oragenics, Inc. (Photo: Business Wire)

“Oragenics is moving forward on a number of fronts, including our collaboration with [Intrexon](#) on novel lantibiotics and our Evora line of oral probiotics for humans and pets,” states Dr. Bonfiglio, President and

CEO, Oragenics, Inc. “The OneMedForum enables Oragenics to share our strategy and growth potential with top institutional investors, business development executives and key opinion leaders in high growth medical technology, health care and life science industries.”

### About Oragenics, Inc.

Oragenics, Inc. is focused on becoming the world leader in novel antibiotics against infectious disease and probiotics for oral health for humans and pets. Oragenics, Inc. has established an exclusive worldwide channel collaboration for lantibiotics, a novel class of broad spectrum antibiotics, with Intrexon Corporation Inc., a synthetic biology company. The collaboration will allow Oragenics access to Intrexon's proprietary technologies with the idea of accelerating the development of much needed new antibiotics that will work against resistant strains of bacteria. Oragenics also develops, markets and sells proprietary probiotics specifically designed to enhance oral health for humans and pets, under the brand names [Evora](#) and [ProBiora](#) in over 13 countries worldwide.

For more information about Oragenics, visit [www.oragenics.com](http://www.oragenics.com). Follow Oragenics on [Facebook](#) and [Twitter](#).

**Safe Harbor Statement:** *Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect the Company's current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a*

*variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to our ability to raise additional capital to sustain our operations beyond June 30, 2012 and those set forth in our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the U.S. Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.*

Photos/Multimedia Gallery Available:

<http://www.businesswire.com/multimedia/home/20130107005636/en/>

**Corporate Contact:**

Oragenics, Inc

Michael Sullivan, 813-286-7900 x246

Chief Financial Officer

Direct: 813-786-6431

[msullivan@oragenics.com](mailto:msullivan@oragenics.com)

or

**Investor Contact:**

LaunchPad IR

Robert Giordano, 1-800-625-2236 x7770

President

Direct: 917-327-3938

[rgiordanonyc@gmail.com](mailto:rgiordanonyc@gmail.com)

Source: Oragenics, Inc.